These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17580240)

  • 1. Assessing antibodies to alpha-galactosidase A in Fabry disease.
    Richards SM
    Clin Ther; 2007; 29 Suppl A():S7-8. PubMed ID: 17580240
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
    Linthorst GE; Aerts JM
    J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
    Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
    Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
    Deegan PB
    J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
    Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
    Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.
    van der Veen SJ; Vlietstra WJ; van Dussen L; van Kuilenburg ABP; Dijkgraaf MGW; Lenders M; Brand E; Wanner C; Hughes D; Elliott PM; Hollak CEM; Langeveld M
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
    Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
    PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
    Lenders M; Brand E
    J Med Genet; 2024 May; 61(6):531-533. PubMed ID: 38538083
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
    Warnock DG; Wallace EL
    J Med Genet; 2024 May; 61(6):534-535. PubMed ID: 38589225
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
    van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
    Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
    Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
    Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 17. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
    Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 20. Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme.
    Bonate PL; Sung C; Welch K; Richards S
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):443-59. PubMed ID: 19789963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.